Tezepelumab (AMG-157/MEDI9929) is a human anti-TSLP antibody that prevents TSLP-TSLPR interactions. A phase 2 trial for moderate to severe AD showed that a greater but not statistically significant percentage of tezepelumab-treated patients showed clinical improvements compared to the placebo ...
资料来源:医药魔方,insight数据库,药明康德,EricLSimpson,《Tezepelumab,ananti-thymicstromallymphopoietinmonoclonalantibody,inthetreatmentofmoderatetosevereatopic7 dermatitis:Arandomizedphase2aclinicaltrial》,PRNewswire,Amgen,华福证券研究所 华福证券 ◼TSLP:特泽利尤单抗销售亮眼,全球BD交易火热 目◼多适应症拓展...
Notably, the validity of TSLP as a therapeutic target in humans was demonstrated in a clinical trial in which asthmatic patients were treated with an anti-TSLP monoclonal antibody36. In this study, we delineate the molecular, structural and mechanistic principles underpinning the extracellular ...
Aiolos Bio, Inc. (“Aiolos” or “the Company”) today announced its launch as a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions.
Mucosal mast cells secrete prodigious amounts of IL-9 and IL-13 in response to IL-33, which contributes to IgE antibody production.37 IL-33 has also been shown to directly stimulate eosinophil differentiation and amplify IgE synthesis.38,39 Identification of the specific cellular responses that ...
("Harbour BioMed") (together with the Company, the "Licensors"), have entered into an exclusive license agreement (the "License Agreement") with Windward Bio AG ("Windward Bio") for SKB378/HBM9378[1], an anti-thymic stromal l...
The company has also completed a phase I clinical trial in China under an IND for the treatment of moderate-to-severe asthma. About Harbour BioMed Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed t...
2. Mako Numazaki, et al. ASP7266, a Novel Antibody against Human Thymic Stromal Lymphopoietin Receptor for the Treatment of Allergic Diseases[J]. J Pharmacol Exp Ther. 2022 Jan;380(1):26-33. 3. https://www.upstreambio.com/ 4. Brusselle GG, Koppelman GH. Biologic therapies for severe...
Because it is known that TSLP induces mast cell development, prevents apoptosis in skin mast cells and it is markedly upregulated in the wheals of patients with chronic spontaneous urticaria, the anti-TSLP monoclonal antibody tezepelumab is undergoing clinical trial assessments for this disease [83...
AgentsAnti-Infective AgentsAnti-Obesity DrugsAntiasthmatic DrugsAntibiotic Resistance and MisuseAntibioticsAntibody ConjugatesAnticancer DrugsAnticoagulantsAntidepressantsAntidepressants: Current Progress and Future ProspectsAntidiabetic DrugsAntiepileptic DrugsAntihypertensive DrugsAntimicrobial AgentsAntimicrobial Peptides: ...